Pharmaceutical

Adcendo and Multitude ink ADC deal potentially worth $1bn

Adcendo will acquire ex-China global rights for Multitude’s tissue factor-targeting ADC.

Aug 21, 2024 - 04:00
Adcendo and Multitude ink ADC deal potentially worth $1bn
Adcendo will acquire ex-China global rights for Multitude’s tissue factor-targeting ADC.
Read the original article

Tags:

Previous Article

Researchers teaching artificial intelligence about frustration in protein folding

Next Article

J&Js Rybrevant plus Lazcluze combination gets FDA approval in NSCLC

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Verve Therapeutics and Lilly partner to advance gene editing programme

Verve Therapeutics and Lilly partner to advance gene ed...

Jun 15, 2023

Ikena fires 35% of staff to funnel funds into clinical oncology programmes

Ikena fires 35% of staff to funnel funds into clinical ...

Jan 19, 2024

U.S. life expectancy rose in 2022, but it remains below its pre-pandemic level

U.S. life expectancy rose in 2022, but it remains below...

Nov 29, 2023